关于使用部分暂时闲置募集资金进行现金管理赎回 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海小方制药股份有限公司（以下简称"公司"）于2025年10月24日召开 了第二届董事会第六次会议、第二届监事会第六次会议，审议通过了《关于上 海小方制药股份有限公司使用部分暂时闲置募集资金进行现金管理的议案》， 公司在保证不影响募集资金投资计划正常进行以及确保资金安全的前提下，拟 使用不超过人民币200,000,000元（含本数）的闲置募集资金进行现金管理，用 于购买期限最长不超过12个月的安全性高、流动性好、满足保本要求的银行存 款类产品（包括但不限于协定性存款、定期存款、大额存单等）。本事项无需 提交公司股东会审议。保荐机构国信证券股份有限公司对本事项出具了无异议 的核查意见。具体内容详见公司在上海证券交易所网站（www.sse.com.cn）及 指定信息披露媒体披露的《关于上海小方制药股份有限公司使用部分暂时闲置 募集资金进行现金管理的公告》（公告编号2025-039）。 截至本公告披露日，公司于2025年11月4日购 ...

证券代码：603207 证券简称：小方制药 公告编号：2026-007 上海小方制药股份有限公司 二、 议案审议情况 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 174 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 106,013,448 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 65.9205 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，董事长方之光先生主持，采用现场投票与网络投 票相结合的表决方式。本次股东会的召集、召开及表决程序符合《公司法》和《公 司章程》的相关规定。 (五) 公司董事和董事会秘书的列席情况 (一) 股东会召开的时间：2026 年 3 月 2 日 (二) 股东会召开的地点：上海市浦东新区银城中路 8 ...

为出具本法律意见书之目的，本所委派律师（以下简称"本所律师"）对公司 提供的与本次股东会有关的文件和事实进行了核查和验证。在本所律师对公司提 供的有关文件进行核查和验证的过程中，本所假设： 上海市石门一路 288 号 兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：(86-21) 5298-5488 传真：(86-21) 5298-5492 关于上海小方制药股份有限公司 2026 年第一次临时股东会之法律意见书 致：上海小方制药股份有限公司 君合律师事务所上海分所（以下简称"本所"）接受上海小方制药股份有限公 司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规 则》（以下简称"《股东会规则》"）等法律、法规、规范性文件（以下简称"法律、 法规"）及《上海小方制药股份有限公司章程》（以下简称"《公司章程》"）的有关 规定，按照律师行业公认的业务标准、道德规范和勤勉尽责精神，就公司 2026 年 第一次临时股东会（以下简称"本次股东会"）有关事宜出具本法律意见书。 1. 提供予本所之文件中的 ...

Core Insights - The article highlights the strategic transformation of Xiaofang Pharmaceutical, focusing on its innovative approach in the external medicine sector and its plans for future growth [3][4][8] Product Development - Xiaofang Pharmaceutical has over 60 products in categories such as digestive, skin, and ENT, with core products like Kexai Lu and Lugan Stone Wash ranking in the top three nationally [4] - The company emphasizes the importance of aesthetics and user experience in product design, moving away from traditional packaging to incorporate modern design elements [4][5] - The company has introduced personalized designs for its products, such as gender-specific versions of Kexai Lu, and has improved usability with patented designs for better safety and efficiency [4][5] New Retail Strategy - Xiaofang Pharmaceutical is leveraging a new retail model to enhance product sales, utilizing platforms like Meituan, Taobao, and JD Health to reach consumers effectively [6] - The company’s Kexai Lu product is currently the most popular in its category on Meituan, indicating strong online demand [6] - To address supply chain challenges, the company has partnered with Jiuzhoutong Group to improve distribution and market coverage [6][7] Industrial Layout - The company is developing a smart factory that integrates intelligent warehousing, manufacturing, and user experience areas, aiming to create a comprehensive health service system [7] - The factory will focus on producing a wide range of products and enhancing user engagement through various applications and scenarios [7] Long-term Development - Xiaofang Pharmaceutical aims to strengthen its core competencies in external medicine while pursuing innovation and breakthroughs in research and development [8] - The company has established partnerships for developing new drugs, including a collaborative project for a novel treatment for hair loss [8] - Approximately 50% of Xiaofang's products are included in the national medical insurance directory, reflecting its commitment to quality and accessibility [8]

Group 1 - The core viewpoint of the article is that the company, Xiaofang Pharmaceutical, is progressing as planned with its "Compound Cebai Tincture" project in collaboration with Shanghai Dermatology Hospital [1] - The company has committed to adhering to relevant laws and regulations regarding timely information disclosure about the project's research and development progress [1]

Group 1 - The article discusses the current state of the property market, highlighting significant trends and shifts in demand and pricing [1] - It notes that there has been a notable increase in property values, with some areas experiencing growth rates exceeding 10% year-over-year [1] - The report emphasizes the impact of economic factors such as interest rates and inflation on the property sector, suggesting that these elements will continue to influence market dynamics [1] Group 2 - The article mentions specific regions that are seeing the most activity, indicating a shift in buyer preferences towards suburban areas [1] - It also outlines the challenges faced by the industry, including supply chain disruptions and labor shortages, which are affecting construction timelines and costs [1] - The report concludes with projections for the upcoming quarter, suggesting a potential stabilization in prices as the market adjusts to current economic conditions [1]

Core Insights - The article highlights the success of Xiaofang Pharmaceutical in the family-oriented external medicine sector, emphasizing its innovative product iterations and marketing strategies to enhance user retention and drive sales growth [1][2][3] Group 1: Product Development and Innovation - Xiaofang Pharmaceutical has focused on continuous product iteration and marketing innovation, launching the W-type Kaisi Lu with a unique packaging design to improve medication effectiveness [2] - The company has developed multiple new sub-brands and products, including Xinlong Hongtun and Long Yidian, targeting specific health needs such as oral ulcers and throat inflammation [2][3] - The company is also working on a new traditional Chinese medicine for hair loss, in collaboration with Shanghai Skin Disease Hospital, aiming to enter a promising market [3] Group 2: E-commerce and New Retail Strategy - Xiaofang Pharmaceutical has embraced the new retail trend, establishing partnerships with major e-commerce platforms like Alibaba Health and JD Health to enhance product visibility and sales [3][4] - The company utilizes Kaisi Lu as a "traffic entry point" for online sales, achieving over 300 million annual exposures on a single platform, and employs cross-selling strategies to promote related products [4][5] - The company is implementing a digital inventory monitoring system to prevent stockouts and ensure timely product availability, enhancing customer satisfaction [5] Group 3: Supply Chain and Operational Efficiency - Xiaofang Pharmaceutical is advancing towards a fully digital supply chain, aiming for real-time responses and efficient inventory management to meet consumer demands [5][6] - The company is constructing a smart factory for external medicine production, focusing on automation and efficiency to support growing production needs [6][7] - The company plans to implement a "dual-wheel drive" strategy, focusing on both technological innovation in drug development and enhancing market access through digital tools [7]

Group 1 - Company Xiaofang Pharmaceutical announced the convening of its second board meeting on February 12, 2026, to discuss the proposal for the re-election of a non-independent director [1] - The meeting was held in a hybrid format, combining in-person and video communication [1] Group 2 - Investors Ge Weidong and Fang Wenyuan each invested 1 billion yuan in Jianghuai, leading to a significant increase in the company's stock price [1] - Historical review indicates that retail investors have experienced both gains and losses when participating in private placements [1]

证券代码：603207 证券简称：小方制药 公告编号：2026-004 上海小方制药股份有限公司 关于公司董事离任暨补选董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一)、提前离任的基本情况 (二)、离任对公司的影响 根据《中华人民共和国公司法》及《公司章程》等有关规定， FANG JACKSON JIA CHEN（方家辰）先生的辞职报告自送达公司董事 会之日起生效，其对于非独立董事职务的辞任不会导致公司董事会成 员低于法定人数，不会影响公司董事会的正常运行，亦不会对公司的 规范运作和日常运营产生不利影响，其非独立董事职务辞任后，仍在 公司担任副总经理职务。 上海小方制药股份有限公司（以下简称"公司"）董事会于2026 年2月12日收到公司董事FANG JACKSON JIA CHEN（方家辰）先生的书 面辞职报告。FANG JACKSON JIA CHEN（方家辰）先生因工作原因，向 公司董事会申请辞去公司董事职务，该辞职报告自送达董事会之日起 生效。 一、董事离任情况 | 姓名 | 离任 职务 | 离任时间 ...

证券代码：603207 证券简称：小方制药 公告编号：2026-005 上海小方制药股份有限公司 关于变更注册资本及修改《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海小方制药股份有限公司（以下简称"公司"或"本公司"）于2026年2 月12日召开了第二届董事会第九次会议，会议审议通过了《关于变更注册资本 及修改<公司章程>的议案》。具体内容如下： 一、注册资本变更 公司已办理完毕 2025 年限制性股票激励计划（以下简称"本次激励计划"） 预留授予股票的登记事项，根据中国证券登记结算有限责任公司上海分公司 于2026年2月2日出具的证券变更登记证明，公司总股本增加260,033股。因此， 本次激励计划预留授予股票办理完毕后，公司注册资本由人民币160,559,967元 增加至人民币160,820,000元，总股本由160,559,967股增加至160,820,000股。 鉴于上述变更，公司对《公司章程》中对应条款进行修订，修订条款如下： | 修订前 | 修订后 | | --- | --- | | ...